Avatar

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Sequencing

By Morie Gertz 8 Videos
March 25, 2020
3 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
10:47
SOHO Highlights: State of the Art and Next Questions

Surveying the Induction and Maintenance Therapy Landscape in Newly Diagnos…

Feat. S. Lonial
15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
25:24
Extracellular Vesicles and Their Role in Patients With Multiple Myeloma

Biologically Based Therapies for MM: Surveying Novel Options

Feat. K. Anderson
06:31
2nd SOHO Italian Conference

Treatment Options for the R/R MM Patients: A Review of the Current Data

Feat. K. Anderson
12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
11:10
Yale Cancer Center

Yale Cancer Center Multiple Myeloma and Gammopathies: Translational Scienc…

Feat. N. Neparidze
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/R …

15:42
Noopur S. Raje

ASCO 2021 Updates on Managing High-Risk Relapsed Multiple Myeloma

05:33
Baptist Health South Florida CME

2021 Advancements in Blood Cancers: Blinatumomab in ALL, Pre-ASCT Inductio…

Feat. G. Koehne
19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple M…

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Firs…

Feat. K. Anderson
15:02
Krina Patel

Clinical Trials in Myeloma in 2018

10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, an…

Feat. S. Jagannath